> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ADC Therapeutics Narrows Loss To $25.3 Million As Research Spending Falls
- URL: https://www.bullished.co/adc-therapeutics-narrows-loss-to-25-3-million-as-research-spending-falls-94964a83/
- Published: 2026-11-09T13:21:29.000Z
- Updated: 2026-11-09T13:21:29.000Z
- Description: ZYNLONTA sales rose to $21 million from $15.8 million, while lower research costs helped reduce operating expenses by 24%.
- Author: Matteo Parrino
- Tags: SEC Filings, ADCT, Industry: Healthcare

[ADC Therapeutics](https://www.bullished.co/tag/adct/), which sells the lymphoma medicine ZYNLONTA, narrowed its third-quarter loss to [$25.3 million](https://www.sec.gov/Archives/edgar/data/0001771910/000162828026071899/adc-20261109.htm?ref=bullished.co) from $41.0 million a year earlier, primarily through lower operating expenses. Results accompanying Monday's SEC filing put product sales at $21.0 million, versus $15.8 million, with ADC crediting higher volumes for the increase.

## Research Cuts Reduce The Loss

ADC's operating expenses fell 24% to $36.1 million. The biggest reduction came in research: spending dropped to [$14.7 million](https://www.sec.gov/Archives/edgar/data/0001771910/000162828026071899/adct-20260930pressrelease.htm?ref=bullished.co) from $26.8 million as the company wound down spending on discontinued programs, finished preparatory research and spent less on ZYNLONTA.

Some personnel costs also moved out of research and into commercial manufacturing, inventory and selling expenses. Product sales costs rose to $2.0 million from $1.2 million, primarily because employees shifted their focus toward commercial manufacturing.

Selling and marketing expenses fell to $8.7 million from $10.7 million. Administrative costs moved the other way, rising to $10.7 million from $8.3 million, primarily because of professional expenses and employee compensation.

The loss per share declined to $0.16 from $0.30; a larger average share count helped reduce that figure alongside lower expenses. ADC's adjusted loss, which excludes stock compensation and certain financing and restructuring items, narrowed to $8.8 million from $25.5 million, or $0.06 per share versus $0.19.

For the first nine months, product sales reached $59.7 million, compared with $51.2 million a year earlier. Operating expenses fell 22% to $126.8 million, and the loss narrowed to $74.8 million from $136.2 million.

## October Financing Buys More Time

ADC ended September with $189.2 million in cash and cash equivalents, down from $261.3 million at the end of December 2025, primarily because of cash used in operations. Those balances precede the company's October restructuring.

That restructuring included an [$86.6 million investment](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326015465/dp254756%5Fex9901.htm?ref=bullished.co) from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX and Nantahala Capital. ADC issued approximately 12.9 million common shares and 48 million warrants exercisable at CHF 0.08.

Loan changes reduced principal to $50 million, eliminated scheduled principal repayments and removed minimum-cash requirements. ADC also removed a $150 million payment owed upon a change of control under its HealthCare Royalty financing agreement. The company said the restructuring extended its expected funding runway into 2029.

## ZYNLONTA's Next Clinical Tests

ADC develops antibody drug conjugates—medicines that pair a tumor-targeting antibody with a cell-killing toxin. ZYNLONTA has accelerated U.S. approval for diffuse large B-cell lymphoma that returns or resists treatment after two or more systemic therapies; ADC sells it directly in the United States and uses partners abroad.

Japanese partner Tanabe Pharma has submitted an approval application to Japan's Ministry of Health, Labor and Welfare for that patient group. Tanabe also signed an exclusive agreement with Nippon Shinyaku to commercialize ZYNLONTA in Japan.

December's American Society of Hematology meeting will include [updated combination-trial results](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5Fex9901.htm?ref=bullished.co) for ZYNLONTA with glofitamab and full late-stage results for its combination with rituximab, presentations ADC announced Wednesday. Studies in marginal zone lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia will also be presented.

“We plan to use these findings to guide our clinical development priorities and regulatory strategy,” ADC Therapeutics Chief Medical Officer Mohamed Zaki said in the [earnings release](https://www.sec.gov/Archives/edgar/data/0001771910/000162828026071899/adct-20260930pressrelease.htm?ref=bullished.co).

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ADC Therapeutics SA (ADCT)](https://www.sec.gov/Archives/edgar/data/0001771910/000162828026071899/adc-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit adct-20260930pressrelease.htm — ADC Therapeutics SA 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001771910/000162828026071899/adct-20260930pressrelease.htm?ref=bullished.co) — SEC EDGAR
- [ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates](https://www.prnewswire.com/news-releases/adc-therapeutics-reports-third-quarter-2026-financial-results-and-provides-operational-updates-302932431.html?ref=bullished.co) — prnewswire.com
- [8-K filed 2026-11-04 — ADC Therapeutics SA (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5Fex9901.htm?ref=bullished.co) — SEC EDGAR
- [8-K filed 2026-10-13 — ADC Therapeutics SA (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326015465/dp254756%5Fex9901.htm?ref=bullished.co) — SEC EDGAR

### More on ADC Therapeutics

- [ADC Therapeutics Sees $21 Million In ZYNLONTA Sales And Cash Lasting Into 2029](https://www.bullished.co/adc-therapeutics-sees-21-million-in-zynlonta-sales-and-cash-lasting-into-2029-8e18cb78/)
- [ADC Therapeutics Seeks To Leave Switzerland For Delaware, Converting Every Share One-For-One](https://www.bullished.co/adc-therapeutics-seeks-to-leave-switzerland-for-delaware-converting-every-share-one-for-9ff5ee68/)
- [Bain Capital Life Sciences Fund Reports 9.99% Passive Stake In ADC Therapeutics](https://www.bullished.co/bain-capital-life-sciences-fund-reports-9-99-passive-stake-in-adc-therapeutics-68037e23/)

[All ADC Therapeutics (ADCT) coverage →](https://www.bullished.co/tag/adct/)